Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.

Int J Dermatol

Department of Dermatology and Cutaneous Surgery, University of Miami, 1444 NW 9th Avenue, Miami, FL 33136, USA.

Published: July 2002

Tumor necrosis factor-alpha (TNF-alpha) is a chemokine secreted by T cells which is thought to play a critical role in the pathophysiology of psoriasis. The monoclonal antibody, infliximab, complexes with TNF-alpha, rendering it inactive. A recent clinical trial has reported the clinical benefit and safety of infliximab in moderate to severe plaque psoriasis. We report a case of rapid response and clinical benefit using infliximab in severe pustular psoriasis of von Zumbusch.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-4362.2002.01543.xDOI Listing

Publication Analysis

Top Keywords

rapid response
8
infliximab severe
8
severe pustular
8
pustular psoriasis
8
psoriasis von
8
von zumbusch
8
clinical benefit
8
infliximab
4
response infliximab
4
psoriasis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!